Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
13 pending office actions • 10 clients • 13 examiners • 13 art units • 0 of 13 (0%) have an AI response strategy ready
Florek & Endres PLLC has 16 pending office actions in Biotechnology & Pharmaceuticals, with 1001 career applications. Its resolved allowance rate is 84.9%, and the average number of office actions per allowance is 3.34. The figures indicate an established prosecution record and an active current workload in a specialized field.
The resolved allowance rate describes historical outcomes, while the action average shows the amount of examination activity associated with allowed matters. Practitioners can use the distinction to assess both results and likely response demands. The pending docket provides a current operational signal, but it should not be treated as a substitute for matter-specific information about claim status or examination posture.
Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 5 (38%) |
| §112 only | 1 (8%) |
| Double-patenting + other | 2 (15%) |
| Multi-statute (no §101) | 5 (38%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FUBARA, BLESSING M | 1 | 62.2% | +34.1% |
| YOUNG, MICAH PAUL | 1 | 55.2% | +30.0% |
| PRONZATI, GINA | 1 | 65.9% | +48.3% |
| SHI, KATHERINE MENGLIN | 1 | 78.3% | +21.8% |
| KEENA, ELLA LORRAINE | 1 | 13.0% | +14.5% |
| SERGENT, RABON A | 1 | 55.1% | +24.1% |
| SMITH, PETER DANIEL | 1 | 51.3% | +48.8% |
| OUSPENSKI, ILIA I | 1 | 77.3% | +20.6% |
| ZHENG, LI | 1 | 83.5% | +13.0% |
| JACKSON, JORDAN L | 1 | 40.4% | +39.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18429075 | DERMAPLANE RAZOR | KEENA, ELLA LORRAINE | 57d |
| 18798138 | CONDITIONED MEDIUM FROM CELLS CULTURED UNDER HYPOXIC CONDITIONS AND USES THEREOF | PRONZATI, GINA | — |
| 18578773 | METHOD FOR THE PRODUCTION OF A SHAPE-MEMORY TISSUE AND RELATIVE USES | SERGENT, RABON A | — |
| 17607842 | CONDITIONED MEDIUM AND METHODS OF USE THEREOF | CORDAS, EMILY ANN | — |
| 17393356 | COMPOSITIONS AND METHODS FOR REDUCING INFLAMMATION | CONNORS, ALEXANDRA F | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18025092 | METHOD FOR THE MANAGEMENT OF ORAL THERAPY IN PARKINSON'S DISEASE | JACKSON, JORDAN L | 155d overdue |
| 18570437 | ADAPTER FOR CLINICAL, MEDICAL AND LABORATORY CONTAINERS | SMITH, PETER DANIEL | 31d overdue |
| 18790134 | MICRODERMABRASION SYSTEM WITH ERGONOMIC HANDLE | SHI, KATHERINE MENGLIN | 15d |
| 18429075 | DERMAPLANE RAZOR | KEENA, ELLA LORRAINE | 57d |
| 18279470 | GENETIC STABILIZER AND GROWTH SELECTOR FOR GENETIC TRANSFORMATION OF THE CHLOROPLAST GENOME OF MICROALGAE | ZHENG, LI | 62d |
| 18947213 | TOPICAL COMPOSITION AND METHOD OF USE | FUBARA, BLESSING M | — |
| 18919763 | STABLE SOLID FINGOLIMOD DOSAGE FORM | YOUNG, MICAH PAUL | — |
| 18798138 | CONDITIONED MEDIUM FROM CELLS CULTURED UNDER HYPOXIC CONDITIONS AND USES THEREOF | PRONZATI, GINA | — |
| Client (Assignee) | Pending OAs |
|---|---|
| AbbVie | 4 |
| Handa Neuroscience, LLC | 1 |
| Envy Medical | 1 |
| Harry'S, Inc. | 1 |
| Fondazione Irccs Policlinico San Matteo | 1 |
| Vertice Pharma LLC | 1 |
| Cardiomix S.r.l. | 1 |
| Luca Dall'Osto | 1 |
| Brain Innovations, S.r.l. | 1 |
| SIFI S.P.A. | 1 |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| 1618 | 1 |
| 1633 | 1 |
| 3771 | 1 |
| 3724 | 1 |
| 1638 | 1 |
| 3781 | 1 |
| 1644 | 1 |
| 1662 | 1 |
| 2857 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18947213 | TOPICAL COMPOSITION AND METHOD OF USE | Allergan Sales, LLC | FUBARA, BLESSING M | 1613 | §102§103§112DP | Non-Final OA | — | Pending | Nov 14, 2024 |
| 18919763 | STABLE SOLID FINGOLIMOD DOSAGE FORM | Handa Neuroscience, LLC | YOUNG, MICAH PAUL | 1618 | §103Other | Non-Final OA | — | Pending | Oct 18, 2024 |
| 18798138 | CONDITIONED MEDIUM FROM CELLS CULTURED UNDER HYPOXIC CONDITIONS AND USES THEREOF | Allergan Sales, LLC | PRONZATI, GINA | 1633 | §102§103§112 | Non-Final OA | — | Pending | Aug 08, 2024 |
| 18790134 | MICRODERMABRASION SYSTEM WITH ERGONOMIC HANDLE | Envy Medical, Inc. | SHI, KATHERINE MENGLIN | 3771 | §112Other | Non-Final OA | 15d | Pending | Jul 31, 2024 |
| 18429075 | DERMAPLANE RAZOR | Harry'S, Inc. | KEENA, ELLA LORRAINE | 3724 | §103§112 | Non-Final OA | 57d | Pending | Jan 31, 2024 |
| 18578773 | METHOD FOR THE PRODUCTION OF A SHAPE-MEMORY TISSUE AND RELATIVE USES | Fondazione Irccs Policlinico San Matteo | SERGENT, RABON A | 1638 | §103§112 | Non-Final OA | — | Pending | Jan 12, 2024 |
| 18570437 | ADAPTER FOR CLINICAL, MEDICAL AND LABORATORY CONTAINERS | Vertice Pharma LLC | SMITH, PETER DANIEL | 3781 | §103 | Final Rejection | 31d overdue | Pending | Dec 14, 2023 |
| 18387237 | AUTOANTIBODIES AGAINST NaV1.5 CHANNEL AS BIOMARKERS FOR THE DIAGNOSIS OF BRUGADA SYNDROME AND RELATED THERAPEUTIC METHODS | Cardiomix S.r.l. | OUSPENSKI, ILIA I | 1644 | §112DP | Non-Final OA | — | Pending | Nov 06, 2023 |
| 18279470 | GENETIC STABILIZER AND GROWTH SELECTOR FOR GENETIC TRANSFORMATION OF THE CHLOROPLAST GENOME OF MICROALGAE | Luca Dall'Osto | ZHENG, LI | 1662 | §103 | Final Rejection | 62d | Pending | Aug 30, 2023 |
| 18025092 | METHOD FOR THE MANAGEMENT OF ORAL THERAPY IN PARKINSON'S DISEASE | Brain Innovations, S.r.l. | JACKSON, JORDAN L | 2857 | §103Other | Final Rejection | 155d overdue | Pending | Mar 07, 2023 |
| 17802588 | FORMULATION BASED ON POLYHEXAMETHYLENE BIGUANIDE FOR USE IN THE TREATMENT OF ACANTHAMOEBA KERATITIS AND/OR FUNGAL INFECTIONS | Sifi S.p.A. | FAY, ZOHREH ALEMZADEH | 1617 | §103 | Non-Final OA | 24d overdue | Pending | Aug 26, 2022 |
| 17607842 | CONDITIONED MEDIUM AND METHODS OF USE THEREOF | Allergan Sales, LLC | CORDAS, EMILY ANN | 1632 | §102§103Other | Final Rejection | — | Pending | Oct 29, 2021 |
| 17393356 | COMPOSITIONS AND METHODS FOR REDUCING INFLAMMATION | Allergan Sales, LLC | CONNORS, ALEXANDRA F | 1634 | §103§112 | Final Rejection | — | Pending | Aug 03, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial84.9% of resolved applications prosecuted by Florek & Endres Pllc were allowed, across 1,001 applications in USPTO records.
3.34 office actions per allowed application on average.
13 pending office actions as of October 2026, for 10 clients, before 13 examiners in 13 art units.
